Showing 4721-4730 of 5910 results for "".
- Modernizing Medicine Releases Enhanced Ophthalmic Image Management to Improve Clinical Workflowhttps://modernod.com/news/modernizing-medicine-releases-enhanced-ophthalmic-image-management-to-improve-clinical-workflow/2479198/Modernizing Medicine announced it has released the latest version of ophthalmic Image Management aimed at helping ophthalmologists save time and deliver efficiency associated with diagnostic imaging workflows. Many ophthalmologists benefit from having an all-in-one solution that bridges da
- RVL Pharmaceuticals Upneeq Wins 2021 MedTech Breakthrough Awardhttps://modernod.com/news/rvl-pharmaceuticals-upneeq-wins-2021-medtech-breakthrough-award/2479196/RVL Pharmaceuticals, a subsidiary of Osmotica Pharmaceuticals, announced that its ptosis drug Upneeq (oxymetazoline hydrochloride ophthalmic solution), 0.1% has been selected as the winner of the “Best New Technology Solution for Drug Delivery” award in the fifth annual MedTech Breakthrough Award
- FDA Authorizes Pfizer, BioNTech’s COVID-19 Vaccine for Younger Adolescentshttps://modernod.com/news/fda-authorizes-pfizer-biontechs-covid-19-vaccine-for-younger-adolescents/2479191/The FDA on Monday expanded the emergency-use authorization (EUA) for Pfizer and BioNTech’s vaccine BNT162b2 to include preventing COVID-19 in adolescents 12 through 15 years of age, according to a FirstWord report. The two-dose mRNA-based vaccine was initially granted an EUA in December for
- Oculis Announces Positive Data From Two Proof-of-Concept Phase 2 Trials With OCS-02 in Dry Eye Disease and Acute Anterior Uveitishttps://modernod.com/news/oculis-announces-positive-data-from-two-proof-of-concept-phase-2-trials-with-ocs-02-in-dry-eye-disease-and-acute-anterior-uveitis/2479192/Oculis announced positive data from two clinical proof of concept phase 2 trials with OCS-02, its novel, topical anti-TNF alpha antibody fragment candidate, in dry eye disease (DED) and acute anterior uveitis (AAU). The data were presented for the first time at ARVO 2021, the annual meeting of th
- Bio-Tissue to Present Webinar in 3-D Showcasing New Treatment Regimen to Diagnose and Treat Mechanical Dry Eyehttps://modernod.com/news/bio-tissue-to-present-webinar-in-3-d-showcasing-new-treatment-regimen-to-diagnose-and-treat-mechanical-dry-eye/2479188/Bio-Tissue announced today that it will present a special 3-D webinar on Wednesday, May 19, 2021, from 8:30 pm to 9:30 pm EDT, hosted by Neel Desai, MD, who will demonstrate his novel surgical technique known as Reservoir Restoration to treat Mechanical Dry Eye (MDE). He will also discuss how to
- Sinopharm’s COVID-19 Vaccine Granted WHO Emergency Listinghttps://modernod.com/news/sinopharms-covid-19-vaccine-granted-who-emergency-listing/2479184/The World Health Organization (WHO) on Friday approved Sinopharm’s COVID-19 vaccine for emergency use, paving the way for millions more doses to be included into the COVAX program in the coming weeks or months for rollout in developing countries, according to a FirstWord report. The decisio
- Clearside Biomedical Announces Multiple Poster Presentations at ARVOhttps://modernod.com/news/clearside-biomedical-announces-multiple-poster-presentations-at-arvo/2479185/Clearside Biomedical announced that multiple clinical poster presentations related to its suprachoroidal injection platform and programs were delivered at the Association for Research in Vision and Ophthalmology 2021 Virtual Meeting which took place May 1-7, 2021.
- New Partnership Expands Alcon’s In-Office Dry Eye and Ocular Health Portfoliohttps://modernod.com/news/new-partnership-expands-alcons-in-office-dry-eye-and-ocular-health-portfolio/2479180/Alcon has gained exclusive rights to sell the technology and accompanying products of BlephEx, a provider of bacterial biofilm theory, in the United States effective May 1, 2021. Terms of the deal were not disclosed. The BlephEx eyelid cleaning device and LashCam iR WIFI
- LumiThera Presents Valeda Treatment Benefits for Photobiomodulation in Early Patients with Diabetic Retinopathy and Macular Edemahttps://modernod.com/news/lumithera-presents-valeda-treatment-benefits-for-photobiomodulation-in-early-patients-with-diabetic-retinopathy-and-macular-edema/2479177/LumiThera announced research investigators presented positive clinical findings following PBM treatment with the Valeda Light Delivery System from an ongoing safety and efficacy study in early diabetic retinopathy (DR) patients with central macular edema (DME) at the Association for Research in V
- Gyroscope Therapeutics Postpones Initial Public Offeringhttps://modernod.com/news/gyroscope-therapeutics-postpones-initial-public-offering/2479176/Gyroscope Therapeutics announced it has postponed plans for its initial public offering. “In light of market conditions, we have decided to postpone our planned initial public offering,” Khurem Farooq, Chief Executive Officer, said in a company news release. “Based on the